FDA Approves Rivaroxaban for Stroke Prevention in AF

The FDA has approved rivaroxaban (Xarelto, Johnson & Johnson) for stroke reduction in people with non-valvular atrial fibrillation. The label will include a boxed warning that people should not discontinue taking the drug without talking with a healthcare professional. The FDA will also require that ...

Related News:-

• FDA Panel Votes for Rivaroxaban (Xarelto): Atrial Fibrillation ...


FDA Panel Recommends FDA Approval of Rivaroxaban (Xarelto) for Stroke Prevention in Atrial Fibrillation (AF or Afib)

• FDA Panel: Approve Rivaroxaban for Stroke Prevention : Internal ...


Internal Medicine News Digital Network is the online destination and multimedia properties of Internal Medicine News, the independent news publication. Our breaking news covers ...

• New Drug Application Submitted to FDA for Rivaroxaban for ...


{Businesswire via BioPortfolio} Johnson & Johnson Pharmaceutical Research & Development, L.L.C. (J&JPRD) announced today that it has sub...

• FDA Advisory Committee Recommends Approval of Oral Anticoagulant ...


{Businesswire via BioPortfolio} Johnson & Johnson Pharmaceutical Research and Development, L.L.C. (J&JPRD) announced today that the U.S. Food an...

• FDA Advisory Committee Recommends Approval of Oral Anticoagulant ...


Johnson & Johnson Pharmaceutical Research and Development, L.L.C. (J&JPRD) announced today that the U.S. Food and Drug Administration&

• MEDDESKTOP: Rivaroxaban for Prevention of Stroke in Patients with ...


izdio, NPI Registry, International Classification of Disesases,ICD,HCPCS, Current Procedural Terminology, CPT, National Drug Codes,NDC, SNOMED CT, MEDCIN, Medical ...

• FDA panel recommends approval of rivaroxaban for stroke prevention ...


An FDA advisory panel voted 9-2 (with 1 abstention) to recommend approval for rivaroxaban (Xarelto, Johnson & Johnson and Bayer AG), an oral, once-daily anticoagulant as a ...

• GEN | Industry Updates: FDA Advisory Committee Recommends Approval ...


Industry Updates: Sep 8, 2011 FDA Advisory Committee Recommends Approval of Oral Anticoagulant Rivaroxaban for the Prevention of Stroke and Systemic Embolism in Patients with ...

• FDA Panel Endorses Xarelto for Stroke Prevention


A U.S. Food and Drug Administration advisory committee has voted 9-2, with one abstention, to recommend that the FDA approve the direct oral factor Xa inhibitor rivaroxaban ...